ICEC0942, an Orally Bioavailable Selective Inhibitor of CDK7 for Cancer Treatment. (2018)

First Author: Patel H
Attributed to:  The Development of Inhibitors of Cdk Activating Kinase (CAK) funded by EPSRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1158/1535-7163.mct-16-0847

PubMed Identifier: 29545334

Publication URI: http://europepmc.org/abstract/MED/29545334

Type: Journal Article/Review

Volume: 17

Parent Publication: Molecular cancer therapeutics

Issue: 6

ISSN: 1535-7163